Clobetasol: Indication, Dosage, Side Effect, Precaution

Concise Prescribing Info Full Prescribing Info

Dosage/Direction for Use Contraindications Special Precautions Adverse Reactions Pregnancy Category (US FDA) Drug Interactions Action Storage CIMS Class ATC Classification

Concise Prescribing Info

Indications/Uses

Corticosteroid-responsive dermatoses.

Dosage/Direction for Use

Adult: Topical As 0.05% oint/cream/lotion/gel/scalp soln: Apply thinly onto the affected area once daily or bid, reduced if necessary. Max dose: 50 g wkly. Max duration of therapy: 4 wk. As 0.05% shampoo: Apply directly on dry scalp once daily. Max duration of therapy: 4 wk. As 0.05% foam: Apply to affected area bid. Max dose: 50g wkly. Max duration of therapy: 2 wk.

Contraindications

Untreated bacterial, fungal or viral skin lesions, rosacea, perioral dermatitis, acne, and plaque psoriasis. Childn <1 yr (oint/cream/lotion/gel/scalp soln); <2 yr (shampoo).

Special Precautions

Childn. Pregnancy and lactation. Patient Counselling Avoid use w/ occlusive dressing. Avoid contact w/ face (i.e. eyes, nose, mouth), axillae, or groin. Clobetasol foam is flammable, do not smoke during or immediately after application. Monitoring Parameters Monitor for hypothalamic-pituitary-adrenal (HPA) axis suppression through ACTH stimulation test, morning plasma cortisol test, and urinary free cortisol test.

Adverse Reactions

Significant: Hypothalamic-pituitary-adrenal (HPA) axis suppression or hypercorticism (i.e. Cushing's syndrome, hyperglycaemia, glycosuria), contact dermatitis, skin irritation. Nervous: Numbness of fingers. CV: Intracranial HTN e.g. bulging fontanelles, headaches, bilateral papilledema. Dermatologic: Burning and stinging sensation, tingling, cracking, itching, dryness, hypopigmentation, erythema, folliculitis, tenderness, telangiectasia, striae, miliaria, alopecia, pustules and tightening of the scalp.

Pregnancy Category (US FDA)

Drug Interactions

Increased systemic exposure w/ CYP3A4 enzyme inhibitors (e.g. itraconazole, ritonavir). May diminish the antineoplstic effect of aldesleukin. May potentiate the hyperglycaemic effect of ceritinib. May diminish the therapeutic effect of corticorelin and hyaluronidase. May enhance the adverse/toxic effects of deferasinox.

CIMS Class

Topical Corticosteroids

ATC Classification

D07AD01 - clobetasol ; Belongs to the class of very potent (group IV) corticosteroids. Used in the treatment of dermatological diseases.

Disclaimer: This information is independently developed by CIMS based on clobetasol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com